Noventure grows in healing technology with new acquisitions

The Spanish company Noventure, which specializes in licensing innovative substance-based medical devices and food supplements, has announced the acquisition of Ulkox/Oleoabrax, a wound-healing technology based on olea europaea leaf extract. The medical devices were originally developed by the Spanish company Quesper R&D, which specializes in the creation and development of medical devices, and Orpea Ibérica, a company in the field of elderly and dependent care and the mental health sector, together with the Andalusian Health Service (SAS).

Olea europea (olive) leaf extract has shown an excellent purifying effect that contributes to the acceleration of skin wound healing. Chronic wounds are mainly seen in the older population. Rising healthcare costs, an aging population, recognition of the threat posed by difficult-to-treat infections such as those associated with biofilms, and the continuing threat of diabetes and obesity worldwide, make chronic wounds a major clinical, social and economic challenge.

From an economic standpoint, the annual market for wound care products is expected to reach between $15 billion and $22 billion by 2024.

Find more details about the company Noventure and the acquisition of Ulkox/Oleoabrax, a wound-healing technology based on olea europaea leaf extract, with our companion app. The Born2Invest mobile app brings you the latest business headlines so you can stay on top of the market.

Noventure expects to become a key player in topical delivery products

Ulkox/Oleoabrax are Noventure’s first olea europaea-based products. They are already available for licensing and have been certified as Class IIb medical devices. They are indicated for the healing of full- or partial-thickness skin wounds. Luciano Conde, CEO of Noventure explains that “this agreement will allow us not only to continue to shape innovative scientific assets and bring them to markets around the world, but also to take steps to become a key player in topically administered medical devices”.

In the words of José Manuel Quesada, CEO of Quesper R&D, “after more than ten years of clinical and preclinical research, we can proudly state that Ulkox/Oleoabrax have the proven ability to reactivate and accelerate the healing process of skin ulcers and wounds, and do so significantly better than other widely used products.”

Noventure is a Spanish company based in Barcelona. It specializes in licensing innovative medical devices based on specialized food substances and supplements. It markets CE-marked medical devices, ready to be marketed in the European Union and territories worldwide, and specialty food supplements in the areas of gastroenterology, urogynecology, pediatrics, and dermatology.

__

(Featured image by photosforyou via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.